Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Adjuncts on RZL-012-Induced Adverse Events
NCT05476679Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Tapencarium in submental fat, sponsored by Raziel Therapeutics. Started Sep 2022; status: completed.
02
Drugs
Tapencarium
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT05476679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476679.